AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24580388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane induction and maintenance (SEVO)
Number of subjects: 60
Study 22298852 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study 20817133 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior non-fearful experiences with the stimulus (preexposure group)
Number of subjects: 0
Study 20817133 — intervention group
Group type: COMPARATOR
Intervention: Standard fear conditioning (paired presentations of a geometric figure and electric shock)
Number of subjects: 0
Study 17993094 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Seal mask
Number of subjects: 60
Study 17993094 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic mask
Number of subjects: 60
Study 15987330 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational experience at a women's safe shelter
Number of subjects: 36
Study 15987330 — intervention group
Group type: COMPARATOR
Intervention: Workshop seminar alone (control)
Number of subjects: 36
Study 12185558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin 500 mg daily for 3 days followed by oral mefloquine 750 mg on day 4
Number of subjects: 42
Study 12185558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin 500 mg daily for 3 days plus oral mefloquine 750 mg on day 1
Number of subjects: 42
Study 12185558 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 750-mg oral dose of mefloquine
Number of subjects: 42
Study 12185558 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin alone for the first 3 days
Number of subjects: 42
Study 12185558 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin and mefloquine combination
Number of subjects: 42
Study 12185558 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone
Number of subjects: 42
Study 12185558 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine after a 3-day regimen of artemisinin
Number of subjects: 42
Study 9455524 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 250 mg daily
Number of subjects: 232
Study 9455524 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 1,000 mg weekly
Number of subjects: 232
Study 9455524 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg daily
Number of subjects: 232
Study 9455524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 7895002 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease subjects
Number of subjects: 64
Study 7895002 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study 1695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 8
Study 1695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 8
Study 1695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terfenadine and flurbiprofen
Number of subjects: 8
Study 1695877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1695877 — intervention group
Group type: EXPERIMENTAL
Intervention: All active drug days (terfenadine, flurbiprofen, combination)
Number of subjects: 8
Study 320477 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus daily granulocyte transfusions from ABO-matched donors
Number of subjects: 31
Study 320477 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 31
Study 30218709 — intervention group
Group type: EXPERIMENTAL
Intervention: VisCubeSX VR anatomic model
Number of subjects: 31
Study 30218709 — intervention group
Group type: COMPARATOR
Intervention: Traditional independent study curriculum
Number of subjects: 31
Study 28950190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical route (TU)
Number of subjects: 42
Study 28950190 — intervention group
Group type: COMPARATOR
Intervention: Lateral transabdominal route (TA)
Number of subjects: 42
Study 28950190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 25537197 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA 809M IOL
Number of subjects: 188
Study 25537197 — intervention group
Group type: COMPARATOR
Intervention: ReSTOR SN6AD1 IOL
Number of subjects: 188
Study 23422376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone (10 to 20 mg as required up to a maximum of 40 mg/d)
Number of subjects: 376
Study 23422376 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg every 4 to 8 hours to a maximum of 20 mg/d)
Number of subjects: 376
Study 23422376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 376
Study 23422376 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 376
Study 20615933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (starting dose 50 mg eq., flexible dosing of 25, 50, 75, or 100 mg eq.)
Number of subjects: 388
Study 20615933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 388
Study 19439457 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe with 400 microg folic acid
Number of subjects: 180
Study 19439457 — intervention group
Group type: COMPARATOR
Intervention: 30 mg Fe with 400 microg folic acid
Number of subjects: 180
Study 19439457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MuMS; 30 mg Fe, 400 microg folic acid, and other micronutrients)
Number of subjects: 180
Study 16460693 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day citalopram
Number of subjects: 100
Study 16460693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15057843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior capsulotomy
Number of subjects: 0
Study 15057843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cingulotomy
Number of subjects: 0
Study 15057843 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcaudate tractotomy
Number of subjects: 0
Study 15057843 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbic leucotomy
Number of subjects: 0
Study 15057843 — intervention group
Group type: EXPERIMENTAL
Intervention: Central lateral thalamotomy/anterior medial pallidotomy
Number of subjects: 0
Study 11680557 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 114
Study 11680557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined individual and family therapy
Number of subjects: 114
Study 11680557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 114
Study 11680557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 114
Study 11680557 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 114
Study 9326834 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline (25 mg t.i.d., 50 mg t.i.d., 75 mg t.i.d.)
Number of subjects: 12
Study 9326834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8145176 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (1 mg decrease every 3-7 days)
Number of subjects: 251
Study 8145176 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (long-term treatment for 5-12 months)
Number of subjects: 251
Study 8145176 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (tapering and discontinuation)
Number of subjects: 251
Study 2427808 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/day nicardipine for 2 weeks
Number of subjects: 8
Study 2427808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(-4) M nicardipine
Number of subjects: 8
Study 2427808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(-8) M nicardipine
Number of subjects: 8
Study 2427808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(-6) M nicardipine
Number of subjects: 8
Study 2427808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(-4) M nicardipine, 10(-8) M nicardipine, 10(-6) M nicardipine
Number of subjects: 8
Study 31405765 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg QD for 5 weeks
Number of subjects: 361
Study 31405765 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg QD for 5 weeks
Number of subjects: 361
Study 31405765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg QD for 5 weeks
Number of subjects: 361
Study 31405765 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 361
Study 29284443 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIA psychotherapy sessions
Number of subjects: 220
Study 29284443 — intervention group
Group type: COMPARATOR
Intervention: BWA only
Number of subjects: 220
Study 25265545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 101
Study 25265545 — intervention group
Group type: COMPARATOR
Intervention: Support and discussion control group
Number of subjects: 101
Study 23860985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle)
Number of subjects: 268
Study 23860985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of stress-dose hydrocortisone (300 mg daily for 7 days maximum)
Number of subjects: 268
Study 23860985 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo plus epinephrine (1 mg/CPR cycle)
Number of subjects: 268
Study 23860985 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of saline placebo
Number of subjects: 268
Study 21523459 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (A) - physiotherapist guided stretching and strengthening exercises, 12 sessions over 12 weeks, with home exercises up to 24 months
Number of subjects: 102
Study 21523459 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment group (B) - normal postoperative treatment or no treatment/self-management
Number of subjects: 102
Study 18295613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (30 minutes a day, 5 days a week for 4 weeks)
Number of subjects: 40
Study 18295613 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 40
Study 16805357 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) apexification (control)
Number of subjects: 15
Study 16805357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) apexification (experimental)
Number of subjects: 15
Study 14594886 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg orally for 12 days)
Number of subjects: 30
Study 14594886 — intervention group
Group type: COMPARATOR
Intervention: Control (30 normal participants)
Number of subjects: 30
Study 11079645 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term vitamin C therapy (intravenous)
Number of subjects: 55
Study 11079645 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term vitamin C therapy (oral)
Number of subjects: 55
Study 11079645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8869533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 0
Study 8869533 — intervention group
Group type: COMPARATOR
Intervention: Survanta
Number of subjects: 0
Study 1740597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned urge-response toileting (PURT) intervention over 12 weeks.
Number of subjects: 113
Study 1740597 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of UI among the experimental group.
Number of subjects: 113
Study 1740597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 113
Study 6603496 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 10
Study 6603496 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous (placebo) stimulation
Number of subjects: 10
Study 31846631 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week daily meal with fresh Hass avocado
Number of subjects: 84
Study 31846631 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric meal (control group)
Number of subjects: 84
Study 31079203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens extraction (LE, phacoemulsification with posterior chamber intraocular lens implantation)
Number of subjects: 122
Study 31079203 — intervention group
Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 122
Study 28924368 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with postoperative ketorolac analgesia
Number of subjects: 50
Study 28924368 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with postoperative fentanyl analgesia
Number of subjects: 50
Study 28924368 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 28924368 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl group
Number of subjects: 50
Study 26869944 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based auditory training (13 sessions over 4 weeks)
Number of subjects: 56
Study 23812612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser and acoustic pressure ultrasound for transepidermal delivery of cosmeceuticals
Number of subjects: 14
Study 23812612 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser alone
Number of subjects: 14
Study 21528595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 60
Study 21528595 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium Bromide (50 mg, 3 times a day for 30 days)
Number of subjects: 60
Study 19366490 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg x d DSR
Number of subjects: 22
Study 19366490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16673738 — intervention group
Group type: EXPERIMENTAL
Intervention: Night vision goggles (NVGs)
Number of subjects: 0
Study 16673738 — intervention group
Group type: COMPARATOR
Intervention: Ambient light
Number of subjects: 0
Study 15293131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-urea breath test
Number of subjects: 255
Study 11535445 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy of external beam therapy
Number of subjects: 42
Study 11535445 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 42
Study 8295092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% chlorhexidine digluconate solution
Number of subjects: 18
Study 8295092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate-sodium bicarbonate (SBSB) compound
Number of subjects: 18
Study 8295092 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study 3471181 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 145
Study 3471181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 145
Study 3471181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 145
Study 3471181 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonitis
Number of subjects: 145
Study 29789518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinoleic (olive oil based)
Number of subjects: 206
Study 29789518 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (soybean oil based)
Number of subjects: 206
Study 26714981 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (808 nm, 250 J/cm², 100 mW, 7 J each point)
Number of subjects: 30
Study 26714981 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser session
Number of subjects: 30
Study 25427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Random (non‐fasting) blood glucose testing (RBGT)
Number of subjects: 5483
Study 25427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian type 2 diabetes risk assessment tool (AUSDRISK)
Number of subjects: 5483
Study 25427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RBGT and AUSDRISK
Number of subjects: 5483
Study 25427845 — intervention group
Group type: COMPARATOR
Intervention: AUSDRISK
Number of subjects: 5483
Study 23566722 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 25
Study 23566722 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered lidocaine
Number of subjects: 25
Study 23566722 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (after adjustment)
Number of subjects: 25
Study 23566722 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered lidocaine (after adjustment)
Number of subjects: 25
Study 20651059 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400 mg twice a day
Number of subjects: 903
Study 20651059 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 903
Study 18982206 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP with heated humidification
Number of subjects: 39
Study 18982206 — intervention group
Group type: COMPARATOR
Intervention: APAP without heated humidification
Number of subjects: 39
Study 16819595 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia touch screen system (MTS)
Number of subjects: 69
Study 16819595 — intervention group
Group type: COMPARATOR
Intervention: Translated patient information leaflet (PIL) plus verbal support
Number of subjects: 69
Study 16819595 — intervention group
Group type: COMPARATOR
Intervention: Fluent English speakers (FE)
Number of subjects: 69
Study 16819595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inhaler technique
Number of subjects: 69
Study 16819595 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler shaking and mouthpiece checking
Number of subjects: 69
Study 16819595 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordination of inspiration and inhaler actuation
Number of subjects: 69
Study 14506483 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g low-fat (40%) spread fortified with 200 microg FA and a placebo tablet
Number of subjects: 13
Study 14506483 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g low-fat placebo spread and a 200 microg FA tablet
Number of subjects: 13
Study 14506483 — intervention group
Group type: COMPARATOR
Intervention: 20 g low-fat placebo spread and a placebo tablet
Number of subjects: 13
Study 10392865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant urokinase (350,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Number of subjects: 107
Study 10392865 — intervention group
Group type: COMPARATOR
Intervention: Low-dose recombinant urokinase (125,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Number of subjects: 107
Study 10392865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant urokinase
Number of subjects: 107
Study 10392865 — intervention group
Group type: COMPARATOR
Intervention: Low-dose recombinant urokinase
Number of subjects: 107
Study 10392865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of recombinant urokinase
Number of subjects: 107
Study 9373124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (0.3%)
Number of subjects: 122
Study 9373124 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual therapy (gentamicin 1.5% and cefuroxime 5.0%)
Number of subjects: 122
Study 8253492 — intervention group
Group type: EXPERIMENTAL
Intervention: BR-16A (Mentat)
Number of subjects: 40
Study 8253492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 4020517 — intervention group
Group type: EXPERIMENTAL
Intervention: Random scaling of the display; addition of flanking bars at varying distances
Number of subjects: 0
Study 4020517 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanking bars too close (less than about 2 arc min) or optically blurred display
Number of subjects: 0
Study 31492775 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention for hypogonadal patients with testosterone replacement therapy
Number of subjects: 66
Study 31492775 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention for newly diagnosed males without testosterone replacement therapy
Number of subjects: 66
Study 31492775 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention for age-matched healthy eugonadal males
Number of subjects: 66
Study 31492775 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypogonadal patients without strength training)
Number of subjects: 66
Study 29980005 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐shot ultrasound (US)‐guided ESP block with 20 ml 0.25% bupivacaine at the T4 vertebral level
Number of subjects: 50
Study 29980005 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 50
Study 29980005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups provided with intravenous patient‐controlled analgesia device containing morphine
Number of subjects: 50
Study 27809882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 62
Study 27809882 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 62
Study 25364676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen 1 (evening dose at 06.00-07.00 pm)
Number of subjects: 13
Study 25364676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen 2 (evening dose at 09.00-10.00 pm)
Number of subjects: 13
Study 25364676 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone regimen (evening dose at 10.00 pm)
Number of subjects: 13
Study 22931628 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheters removed at 6-8 hours after cesarean section
Number of subjects: 138
Study 22931628 — intervention group
Group type: COMPARATOR
Intervention: Indwelling urinary catheters removed at 24 hours after cesarean section
Number of subjects: 138
Study 20565156 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention for divorced families
Number of subjects: 240
Study 20565156 — intervention group
Group type: EXPERIMENTAL
Intervention: Program for mothers only
Number of subjects: 240
Study 20565156 — intervention group
Group type: EXPERIMENTAL
Intervention: Program participation
Number of subjects: 240